Immune cells engineered to fight deadly childhood brain tumors enter human trials
NCT ID NCT07501156
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new therapy using a patient's own immune cells, engineered to target a specific mutation found in diffuse midline glioma and DIPG, aggressive brain tumors. About 30 participants with recurrent or refractory disease will receive one to two infusions of these cells. The goal is to see if the treatment is safe and can shrink tumors or slow progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- H3K27M-specific engineered immune effector cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could provide a new treatment option for a rare and aggressive brain cancer that currently has few effective therapies.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. The therapy involves infusions of modified immune cells, which can cause serious side effects like inflammation or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.